The Ledger

19.6 billion dollars: that is the new United States manufacturing commitment nine more drugmakers signed onto this week, in a drug pricing deal that now covers 89 percent of the branded drug market. The White House announced August 31, 2026 that Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB have signed “most favored nation” (MFN) pricing agreements, bringing the total to 26 pharmaceutical manufacturers in the voluntary program the administration built around a May 2025 executive order. Under the deals, the nine companies will cut prices on outpatient drugs for every state Medicaid program to match what they charge in wealthy foreign markets, and in exchange get exemption from a separate MFN pricing push aimed at Medicare plus protection from pharmaceutical tariffs; four of the nine, Astellas, Sun Pharma, Teva, and UCB, additionally agreed to donate active pharmaceutical ingredients, including 163 tons of the seizure drug levetiracetam from UCB and 45 metric tons of the antibiotic metronidazole from Teva, to a federal strategic stockpile meant to cut reliance on foreign API supply. The administration says the program has generated more than 700 million dollars in savings through its TrumpRx direct-to-consumer platform since its February 2026 launch and projects 600 billion dollars in savings over the next decade, figures that come from the White House itself and have not been independently verified. Confidence: High on the deal terms, company list, and manufacturing and stockpile commitments, drawn directly from the White House’s own fact sheet. Low on the administration’s own savings and projection figures, which are self-reported and unaudited. Sources: Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans, The White House, Trump strikes new drug pricing deals with nine midsized drugmakers, CNBC, Trump says more drug companies agree to voluntarily lower drug prices, STAT News.

17 billion dollars: that is what a global insurance brokerage giant is paying, in cash, for a rival broker that handles employee health benefits for thousands of American employers. Aon plc announced August 31, 2026 a definitive agreement to acquire USI Insurance Services from private equity firm KKR and other shareholders for 17 billion dollars, or 16.7 billion dollars net of tax attributes, roughly 14.5 times USI’s synergized trailing twelve-month adjusted earnings before interest, taxes, depreciation and amortization (EBITDA). USI, the 10th largest U.S. insurance broker with about 3 billion dollars in annual revenue, 10,500-plus employees, and nearly 200 offices, sells commercial property and casualty coverage alongside employee benefits and health insurance brokerage to middle-market employers, the deal follows Aon’s 13 billion dollar purchase of NFP in 2024 and is meant to build what Aon chief executive Greg Case called “the premier U.S. middle-market platform”; Aon expects 395 million dollars in annual run-rate net EBITDA synergies and plans to fund the all-cash deal entirely with new debt while keeping its current credit ratings. USI’s chairman and chief executive Mike Sicard will become president of Aon plc and global chief executive of its middle-market business once the deal closes, expected in the fourth quarter of 2026 subject to regulatory approval; the combination concentrates more employer health insurance shopping and benefits administration, for millions of workers nationally, into fewer, larger brokerage platforms. Confidence: High on the deal terms, financing, and structure, drawn directly from Aon’s own press release and its own 8-K exhibit filed with the U.S. Securities and Exchange Commission (SEC). Sources: Aon to acquire USI to establish the premier U.S. middle-market platform, Aon plc, Aon strikes $17 billion deal for rival USI Insurance Services, CNBC.

600 million dollars: that is the capital commitment behind a hospital merger taking effect today, the price a state attorney general extracted to keep a Level 1 trauma center’s doors open for the next decade. Sanford Health, a South Dakota-based nonprofit system, and North Memorial Health, based in the Minneapolis suburb of Robbinsdale, completed their merger effective September 1, 2026, after Minnesota Attorney General Keith Ellison secured a 10-year oversight agreement August 28, 2026 under the state’s health care transaction law; the deal commits Sanford to invest 500 million dollars expanding Maple Grove Hospital and 100 million dollars upgrading Robbinsdale Hospital, plus a 15 million dollar anchor contribution over three years for rural providers across greater Minnesota. The oversight agreement legally binds Sanford to maintain Robbinsdale’s Level 1 trauma center and its emergency department, cardiac catheterization lab, labor and delivery, intensive care, stroke, rehabilitation, and mental health services for 10 years, to honor existing union contracts and bar noncompete clauses in new employment agreements, to keep current air and ground ambulance service levels, and to preserve reproductive health care and gender-affirming care consistent with applicable law; Sanford must also meet quarterly with the Attorney General’s office and file annual compliance reports for the full 10 years, a materially more binding structure than Sanford’s failed 2023 attempt to merge with Fairview Health. Confidence: High on the deal terms and oversight commitments, drawn directly from the Minnesota Attorney General’s own press release. Sources: Sanford Health, North Memorial Health enter into 10-year oversight agreement with Attorney General’s Office, Minnesota Attorney General’s Office, Sanford Health, North Memorial merger approved under 10-Year Minnesota oversight agreement, Dakota News Now.

35 million dollars: that is the new funding behind an experimental pill for a rare, aggressive liver infection that has no approved cure. EIT Pharma, a biotechnology company developing therapies for infectious diseases, announced August 31, 2026 it closed an oversubscribed 35 million dollar Series A financing round led by Propel Bio Partners, with participation from Good Ventures, Arrowtown, and other investors. The company will use the proceeds to continue U.S. Food and Drug Administration (FDA) review activities and build manufacturing and commercial readiness, contingent on approval, for lonafarnib, an oral drug targeting hepatitis delta virus (HDV), a rare and severe co-infection of hepatitis B that accelerates liver damage and has no FDA-approved cure today, while also advancing the rest of the company’s infectious-disease pipeline. Confidence: High on the funding terms and investor list, drawn directly from the company’s own release. Low on lonafarnib’s ultimate approval and commercial prospects, which depend on an FDA review still in progress. Source: EIT Pharma Closes Oversubscribed $35 Million Series A Round, Led by Propel Bio Partners, BioSpace.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
USI Insurance Services	Aon plc	Insurance brokerage, employee benefits and health insurance middle market	$17 billion cash ($16.7 billion net); announced August 31, 2026, expected to close Q4 2026	Aon to acquire USI, Aon plc
North Memorial Health	Sanford Health	Nonprofit hospital system merger	$600 million capital commitment ($500M Maple Grove, $100M Robbinsdale) plus $15M rural anchor contribution; effective September 1, 2026	Sanford Health, North Memorial Health 10-year oversight agreement, Minnesota Attorney General’s Office
EIT Pharma	Propel Bio Partners (led), Good Ventures, Arrowtown	Biopharma, infectious disease	$35 million Series A (oversubscribed); announced August 31, 2026	EIT Pharma Closes Oversubscribed $35 Million Series A Round, BioSpace

This run’s scan of FTC and DOJ merger actions and state transaction-review dockets found no new healthcare antitrust complaints or consent orders in the last 24 to 48 hours. A frontier check on medical office building dealmaker Big Sky Medical, a Ledger branch not touched in the last three issues, found no new acquisition announced since its July 2026 activity; worth checking again once its next deal lands. An open-ended scan for deals outside the standing source stack surfaced nothing dated to this window beyond what is reported above.